Drug Search Results
More Filters [+]

Mercaptopurine

Alternative Names: mercaptopurine, 6-mercaptopurine, purinethol, puri-nethol, xaluprine, thiopurine, purixan
Latest Update: 2024-09-04
Latest Update Note: Clinical Trial Update

Product Description

Mercaptopurine is a medication used in the management and treatment of acute lymphoblastic leukemia. It is in the class of medications known as purine antagonists. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK557620/)

Mechanisms of Action: Immunosuppressive

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Singapore | Slovakia | Slovenia | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Vietnam

Approved Indications: Acute Leukemia | Acute Lymphoid Leukemia | Leukemia | Lymphoid Leukemia | Acute Leukemia | Acute Lymphoid Leukemia | Leukemia | Lymphoid Leukemia

Known Adverse Events: Anemia | Thrombocytopenia | Neutropenia | Anorexia | Diarrhea | Leukopenia | Macrophage Activation Syndrome | Lymphoma | T-Cell Lymphoma | Contraception

Company: G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Mercaptopurine

Countries in Clinic: Australia, Austria, Belgium, Canada, China, Czech Republic, Denmark, Finland, France, Germany, Hungary, Ireland, Israel, Italy, Netherlands, Norway, Poland, Portugal, Russia, Slovakia, Spain, Sweden, Switzerland, United States

Active Clinical Trial Count: 14

Highest Development Phases

Phase 3: Acute Lymphoid Leukemia|Colitis, Ulcerative|Histiocytosis|Leukemia|Lymphoid Leukemia|Lymphoma|Lymphoma, Non-Hodgkin|Precursor Cell Lymphoblastic Leukemia-Lymphoma

Phase 2: B-Cell Leukemia|Lymphoma, B-Cell|Oncology Solid Tumor Unspecified|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

TINI 2

P2

Recruiting

Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma

2028-12-01

AIEOP-BFM ALL 2017

P3

Recruiting

Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Lymphoid Leukemia

2028-07-14

AIEOP-BFM ALL 2017

P3

Active, not recruiting

Acute Lymphoid Leukemia

2028-06-07

SJALL23H

P2

Not yet recruiting

Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Lymphoid Leukemia

2028-05-01

Recent News Events